BioNTech to Establish Regional Headquarters for South East Asia and First mRNA Manufacturing Facility in Singapore
The setting up of its regional headquarters in Singapore is part of BioNTech’s global expansion strategy, and the fully integrated mRNA manufacturing facility will provide regional and global supply capacity of BioNTech’s product candidates. It will also be equipped to address potential pandemic threats in the region.
The site, which is expected to be operational by 2023, will leverage cutting-edge manufacturing and digital infrastructure, and be equipped to produce various mRNA vaccines and therapeutics for infectious diseases and cancer. It is expected to have highly automated and end-to-end mRNA production capabilities across drug substance, drug product, and fill-and-finish, and to be able to produce several hundred million doses of mRNA-based vaccines.
The project is supported by the Singapore Economic Development Board, whose Chairman, Dr. Beh Swan Gin said, “The investment will enable Singapore to develop capabilities in an important new therapeutic modality as part of the strategy to grow our biopharmaceutical industry. In particular, BioNTech’s mRNA manufacturing facility will contribute
significantly to the region’s ability to address future pandemic threats.”
Commenting on this strategic step in expanding its production network and capacity worldwide, Ugur Sahin, M.D., CEO and Co-founder of BioNTech stated, “Singapore provides an excellent business climate, growing biotechnology industry, and rich talent base. We would like to thank Singapore’s Economic Development Board who has been very
supportive throughout our planning process and we look forward to contributing our technology and expertise to the development of the biotechnology industry in Singapore and this region.”
Biopharmaceutical New Technologies develops novel immunotherapy for cancer and other serious diseases and has a vast portfolio of oncology product candidates. With its deep expertise in mRNA vaccine development, it is also developing a range of mRNA vaccine candidates with its collaborators for multiple infectious diseases. The company has a network of global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, visit www.BioNTech.de.